Zymeworks INC Form 4 insider transactions

EcoR1 Capital, a significant shareholder in Zymeworks Inc., has increased its holdings through a series of open market purchases between March 17 and March 19, 2025.

EcoR1 Capital, a significant shareholder in Zymeworks Inc., has increased its holdings through a series of open market purchases between March 11 and March 13, 2025.

EcoR1 Capital, a significant shareholder in Zymeworks Inc., has increased its holdings through recent purchases of common stock.

EcoR1 Capital, a significant shareholder in Zymeworks Inc., has increased its holdings through a series of common stock purchases between January 13th and January 15th, 2025.

EcoR1 Capital, a significant shareholder in Zymeworks Inc., has increased its holdings through recent purchases of common stock.

Leone D. Patterson, EVP, Chief Bus & Fin Officer at Zymeworks Inc., acquired 79,000 stock options and 53,000 restricted stock units on January 10, 2025.

Zymeworks' Chief Scientific Officer, Paul Andrew Moore, acquired 79,000 stock options and 53,000 restricted stock units on January 10, 2025.

Zymeworks' EVP & Chief Medical Officer, Jeffrey T.L. Smith, was granted stock options and restricted stock units on January 10, 2025.

Zymeworks CEO Kenneth Galbraith was granted 288,000 stock options and 192,000 restricted stock units on January 10, 2025.

Zymeworks' Chief Scientific Officer, Paul Andrew Moore, executed stock transactions on January 6, 2025, involving the vesting of restricted stock units and subsequent sales to cover tax obligations.

Zymeworks CEO Kenneth Galbraith acquired and sold shares of common stock on January 6, 2025, following the vesting of restricted stock units, with sales primarily covering tax obligations.

Zymeworks' EVP & Chief Medical Officer, Jeffrey T.L. Smith, sold 11,110 shares to cover tax obligations following the vesting of restricted stock units.

EcoR1 Capital, a significant shareholder in Zymeworks Inc., has increased its holdings through a series of share purchases in late December 2024 and early January 2025.

EcoR1 Capital, along with related entities, has increased its holdings in Zymeworks Inc. through a series of common stock purchases between December 24th and December 27th, 2024.

EcoR1 Capital, a significant shareholder of Zymeworks Inc., filed an amended SEC Form 4 to include previously omitted stock purchases made in December 2024.

EcoR1 Capital, LLC and related parties acquired pre-funded warrants convertible into common stock of Zymeworks Inc., increasing their potential ownership stake.

Zymeworks Inc. has granted stock options to Derek John Michael Miller, exercisable at $13.06 per share, vesting after the next annual general meeting.

Zymeworks Inc. has granted stock options to Carlos Campoy, exercisable for 31,000 common shares at a price of $13.06 per share.

Zymeworks Inc. has granted stock options to Alessandra Cesano, exercisable at $13.06 per share, vesting after the next annual general meeting.

Zymeworks Inc. has granted stock options to Neu Kelvin, exercisable for 31,000 common shares at a price of $13.06 per share.

Zymeworks Inc. grants stock options to an executive, vesting after the next annual general meeting.

Zymeworks Inc. has granted stock options to Troy Cox, exercisable at $13.06 per share, vesting after the next annual general meeting.

Zymeworks Inc. has granted stock options to an executive, exercisable at $13.06 per share, vesting after the next annual general meeting.

Zymeworks Inc. has granted stock options to Neil Gallagher, exercisable at $13.06 per share, vesting after the next annual general meeting.

Leone D. Patterson, EVP, Chief Business and Financial Officer of Zymeworks Inc., reports the acquisition of 360,000 stock options.

Director Neil Gallagher acquired 74,000 stock options in Zymeworks Inc. on April 2, 2024.